RXC007 ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
85	特発性間質性肺炎	2

85. 特発性間質性肺炎

---

臨床試験数 : 627 /  薬物数 : 443 - (DrugBank : 120) / 標的遺伝子数 : 99 - 標的パスウェイ数 : 212

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05570058 (ClinicalTrials.gov)	September 8, 2022	28/9/2022	Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis	A Multi-Cohort, Randomised, Placebo-Controlled Phase 2a Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Ascending Doses of RXC007 in Patients With Idiopathic Pulmonary Fibrosis	IPF;Fibrosis	Drug: RXC007;Drug: Placebo	Redx Pharma Plc	Simbec Research	Recruiting	40 Years	80 Years	All	64	Phase 2	Belgium;Czechia;Italy;Spain;United Kingdom
2	NCT04931147 (ClinicalTrials.gov)	May 13, 2021	4/6/2021	A 3-part Study to Evaluate Safety, Tolerability, Food Effect and Drug-drug Interactions of RXC007 in Healthy Volunteers	A Randomised, Double-blind, Placebo-controlled, SAD/MAD First-in-human, Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of RXC007 Including Evaluation of Drug-Drug Interaction and Food Effect in Male Participants	Fibrosis;Inflammation;Idiopathic Pulmonary Fibrosis;Non-alcoholic Steatohepatitis;Liver Diseases;Kidney Diseases	Drug: RXC007;Drug: RXC007 Matching Placebo	Redx Pharma Plc	Simbec Research	Recruiting	18 Years	55 Years	Male	80	Phase 1	United Kingdom